Lycia Therapeutics (Nasdaq: LYCA) is a clinical-stage biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop therapeutics that degrade extracellular and membrane-bound proteins. These proteins drive a wide range of difficult-to-treat diseases, including autoimmune, inflammatory, and allergic conditions. Lycia was established in 2019 in collaboration with academic founder and Nobel Laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University. In October 2026, Lycia completed an initial public offering, and its common stock now trades on the Nasdaq Global Select Market under the ticker symbol “LYCA.” Lycia is headquartered in South San Francisco. Visit https://lyciatx.com/ for more information.
Lycia Therapeutics is seeking an experienced, team-oriented, Associate Scientist with a strong biochemistry or biophysics background to help evaluate novel protein-based therapeutics.
The candidate will work closely with members of the Biology and Biologics groups as part of an innovative research organization to advance LYTACs to the clinic.